- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Phase classification: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Apr 11, 2024
P2, N=93, Completed,
This research lays a strategic foundation for targeted interventions against drug-resistant TB, highlighting ligand 2's potential for advanced drug development strategies. Phase classification: P2a --> P2
- |||||||||| GSK2556286 / GSK, TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research, SPR720 / Spero Therap
Review, Journal: Pyrimidine derivatives with antitubercular activity. (Pubmed Central) - Dec 4, 2022
In the first part, the review discusses the pyrimidine compounds according to their targets, pinpointing the structure-activity relationships of each pyrimidine family. The second part of this review is concentrated on antitubercular pyrimidine derivatives with a yet unexplored or speculative target, dividing the compounds according to their structural types.
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Trial completion: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Nov 28, 2022
P2a, N=93, Completed,
The second part of this review is concentrated on antitubercular pyrimidine derivatives with a yet unexplored or speculative target, dividing the compounds according to their structural types. Recruiting --> Completed
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Trial completion date, Trial primary completion date: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Jun 8, 2022
P2a, N=90, Recruiting,
Recruiting --> Completed Trial completion date: Dec 2022 --> Aug 2022 | Trial primary completion date: Dec 2022 --> Aug 2022
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Trial completion date, Trial primary completion date: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Mar 28, 2022
P2a, N=90, Recruiting,
Trial completion date: Dec 2022 --> Aug 2022 | Trial primary completion date: Dec 2022 --> Aug 2022 Trial completion date: Feb 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> Dec 2022
- |||||||||| rifampicin / Generic mfg.
Journal: Exploring targets of cell wall protein synthesis and overexpression mediated drug resistance for the discovery of potential M. tb inhibitors. (Pubmed Central) - Feb 8, 2022
The early detection of mycobacterium tuberculosis can be permanently cured by DOTS comprising Pyrazinamide (Z), Isoniazid (H), Rifampin (R) and Ethambutol (E)...Overexpression of these genes may produce drug-resistant due to dose misuse or the intake of quality compromised anti tubercular drug regimen. Therefore, in the present review there has been a necessity to report the second line antitubercular chemotherapeutics to target various proteins which are the building block of M. tb cell wall, overexpression of which may produce drug resistance.
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research, OPC-167832 / Otsuka, macozinone (PBTZ169) / Innovative Medicines for Tuberculosis, Nearmedic, Bill & Melinda Gates Foundation
PK/PD data, Preclinical, Journal: Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832. (Pubmed Central) - Nov 4, 2021
Superior efficacy was observed for OPC-167832 even at low dose levels, which can be attributed to its low MIC, favorable distribution and sustained retention above the MIC throughout the dosing interval in caseous necrotic lesions where the majority of bacteria reside in C3HeB/FeJ mice. These results support further progression of the three drug candidates through clinical development for tuberculosis treatment.
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Trial completion date, Trial primary completion date: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Jan 20, 2021
P2a, N=90, Recruiting,
Study identified ZINC000170252277 as a potential hit compound for further biological evaluation as DprE1 inhibitor. Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Dec 2020 --> Jan 2022
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Enrollment open: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Aug 9, 2020
P2a, N=90, Recruiting,
Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Dec 2020 --> Jan 2022 Suspended --> Recruiting
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Trial suspension: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Mar 19, 2020
P2a, N=90, Suspended,
Suspended --> Recruiting Recruiting --> Suspended
- |||||||||| TBA-7371 / Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
Enrollment open: Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis (clinicaltrials.gov) - Jan 13, 2020
P2a, N=90, Recruiting,
Recruiting --> Suspended Not yet recruiting --> Recruiting
|
